Literature DB >> 30932416

Time-dependent cytotoxicity of dichloroacetate and metformin against Lewis lung carcinoma.

D L Kolesnik1, O N Pyaskovskaya1, Yu R Yakshibaeva, G I Solyanik1.   

Abstract

The use of inhibitors of energy metabolism of malignant cells is a new promising trend in the treatment of cancer patients, based on one of the unique features of the malignant cell, namely the dominance of glycolysis over oxidative phosphorylation, even in the presence of oxygen, the so-called Warburg effect. AIM: To study time-dependent cytotoxicity of sodium dichloroacetate (DCA) and metformin (MTF) against metastatic tumor cells and action of these agents on tumor cell migration.
MATERIALS AND METHODS: In the study low metastatic LLC/R9 variant of Lewis lung carcinoma was used. The number of living cells in the cytotoxic test was evaluated using sulforhodamine B after 1, 2 and 3 days of cell incubation in vitro. The parameters of the sensitivity of tumor cells to the action of DCA and MTF in vitro were calculated using nonlinear and linear regression of experimental data. The effect of DCA and MTF on cellular motility in vitro was evaluated using a Boyden chamber by calculation of the number of cells that migrated to the bottom side of the filter within 3 days of incubation. The statistical analysis of the data was carried out with the use of descriptive methods, Student's t-criterion, nonlinear, and linear regression analysis.
RESULTS: IC50 of DCA was found to be equal to 50.8 ± 7.6 mM at the first day of incubation with LLC/R9 cells and decreased by 1.9 (p < 0.05) and 2.1 (p < 0.05) times at the 2nd and 3rd days, respectively. Despite the almost identical ІC50 at the 2nd and 3rd days, an increase in the incubation period of cells with DCA for up to 3 days increased the C0 parameter, which reflects the maximum concentration of the agent that does not exhibit cytotoxic effects, by 93% (p < 0.05) compared to this at the 2nd day (16.2 ± 1.4 mM vs 8.4 ± 1.0 mM, correspondently). Unlike DCA, the LLC/R9 cell population was not homogeneous by the sensitivity to the action of MTF; at least at the 3rd day, an appearance of MTF-resistant subpopulation was observed, accounting for 35% of all cells. IC50 of MTF was equal to 12.1 ± 0.6 mM, and unlike DCA, this index progressively decreased at the 2nd and 3rd days by 1.4 (p < 0.05) and 9.3 times (p < 0.05) respectively. Action of DCA at a concentration of 25 mM alone and in combination with MTF at the concentrations of 0.1 mM and 0.7 mM resulted in an increase in cell migration by 65% (p < 0.05), 63% (p < 0.05) and 78.5% (p < 0.05), respectively. There was no significant effect of MTF on the tumor cell migration.
CONCLUSIONS: The sensitivity of the metastatic Lewis lung carcinoma cells to the action of the modifiers of the energy metabolism increased significantly with an increase in the incubation period, apparently, primarily due to the shortage of nutrient substrates and, in particular, glucose, indicating the relevance of their combined use as well as with other agents, which promote the deficiency of glucose in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30932416

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  6 in total

1.  Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance.

Authors:  Maomao Tang; Yuzhe Huang; Xiao Liang; Yaotian Tao; Ning He; Zhenbao Li; Jian Guo; Shuangying Gui
Journal:  AAPS PharmSciTech       Date:  2022-04-29       Impact factor: 3.246

Review 2.  Looking for the Holy Grail-Drug Candidates for Glioblastoma Multiforme Chemotherapy.

Authors:  Beata Pająk
Journal:  Biomedicines       Date:  2022-04-26

3.  Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy.

Authors:  Weiwei Wang; Junting Fan; Guang Zhu; Jing Wang; Yumei Qian; Hongxia Li; Jianming Ju; Lingling Shan
Journal:  Int J Nanomedicine       Date:  2020-04-24

4.  Metabolic Response of Pancreatic Carcinoma Cells under Treatment with Dichloroacetate.

Authors:  Benedikt Feuerecker; Philipp Biechl; Christian Veltkamp; Dieter Saur; Wolfgang Eisenreich
Journal:  Metabolites       Date:  2021-05-30

Review 5.  Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications.

Authors:  Tiziana Tataranni; Claudia Piccoli
Journal:  Oxid Med Cell Longev       Date:  2019-11-14       Impact factor: 6.543

6.  Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.

Authors:  Katharina Klose; Eva-Maria Packeiser; Petra Müller; José Luis Granados-Soler; Jan Torben Schille; Sandra Goericke-Pesch; Manfred Kietzmann; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2021-09-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.